---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-058118"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T15:01:22.091953+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Akebia amends Auryxia supply agreement with Siegfried; extends term to Dec 2024 with option to 2026

## Summary
- Amendment No. 5 to Master Manufacturing Services and Supply Agreement with Siegfried Evionnaz SA.
- Akebia commits to purchase minimum quantity of Auryxia drug substance at predetermined price.
- Term extended to Dec 31, 2024; Company has option to extend to Dec 31, 2026 with 12 months notice.
- No other financial terms disclosed in the filing.

## SEC filing metadata
- accession: 0001193125-23-058118
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000119312523058118/0001193125-23-058118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000119312523058118/d447916d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-058118
- JSON: https://secwatch.observer/filing/0001193125-23-058118.json
- Plain text: https://secwatch.observer/filing/0001193125-23-058118.txt

## Key facts
- Material Agreements
  Akebia Therapeutics, Inc. amended Amendment No. 5 to Master Manufacturing Services and Supply Agreement with Siegfried Evionnaz SA (effective 2022-02-28).
  - Action: amendment
  - Agreement: supply
  - Counterparty: Siegfried Evionnaz SA
  - Effective: 2022-02-28
  source text: On February 28, 2022, Keryx Biopharmaceuticals, Inc., a wholly-owned subsidiary of Akebia Therapeutics, Inc. (the “Company”), and Siegfried Evionnaz SA (“Siegfried”) entered into Amendment No. 5 to Master Manufacturing Services and Supply Agreement (the “Amendment”), which further amends the Master Manufacturing Services and Supply Agreement dated December 20, 2017 (as amended, the “Supply Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312523058118/0001193125-23-058118-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.